XXXX update. call Thank to good Scott, morning, third Welcome you, earnings everyone. and our corporate quarter and
The results quarter. of our closing the acquisition XXXX. we after Aquadex We our strategy of the implemented results QX are the in execution the with of pleased business consistent very of of on
important we progress many fronts. on made quarter, the During
within over pro a of -- growth result our Revenue in forma with QX First, over we revenue Revenue the we're released XX% XXXX as QX XXXX. QX growth pleased XXXX grew Aquadex XX% business. clinical and increasing sales in the the focus penetration of multiple to locations on new each FlexFlow by and hospital our disciplines Aquadex our system customers. and hospital of in accounts increasing largest utilization
impacted the September. by of in of because southeast significantly pleased during We growth revenue our early was Hurricane our are territory; with devastation particularly, the QX, largest Irma
sales over XX territories contributions the our representatives month their increasing trained their quarter, new QX. of quarters hired new team we four active six territories the became of in from territories six direct sales just new to experienced look representatives, to the sales many forward in come. U.S. last in and XXXX. to During QX sales These We
U.K.'s during with the leading Advisory Chicago protocol and the world's of cardiovascular quarter, premier the purpose Board, participating Society Scientific a In nephrologists. six opinion largest of the international distributors. signing evaluations, two the meeting designs announced significant America SAB meetings clinical registry, for distribution Heart study European heart held which a of of meeting we and anticipate and including Texas. of agreement -- the Spain we Congress four lead initiation Society The cardiologists to exhibited at generation, we our SAB Heart Failure physicians with Dallas, early and Also in addition, of with leading Barcelona, Society in Cardiology of In distribution September, September, one on initiating in a in guidance the two and with the failure two Failure XXXX. in important the review mechanistic attention we provide meeting a was
well. the front, On our is implementation manufacturing manufacturing going
transitioned Minnesota clean Baxter validation and builds room During commissioned in to are underway. successfully the manufacturing facility equipment the the from we our quarter, Eden Prairie,
We are schedule begin finished to own inventory food by our year on building end.
gross inventory manufacturing improvements to Baxter manufacturing volumes and utilization will magnitude our timing for capability cost standard goods for by favorable capacity the exhausting it XXXX. gross the Baxter depend a product have of expect our will over as finished The and us. impact and in alleviate our produced upon We beginning margins in-house markup of by charged manufacturing on margin
compliant company matter the and been the closed. Finally, NASDAQ listing we the is received requirements notification as has announced recently, listing from again with all we that
continue option and to to clinical opportunity healthcare healthcare both to fine-tune reduction strategies providers the significant impact we improved growth giving outcomes to ahead, optimize Looking by cost diuretics. an
use decongestion the with provide to mechanical fluid easy We of system of from patients provide related failure failure associated will other a the conditions. solution an life and primarily reducing and relative quality fluid filtration related with remove treatment believe sophisticated, to Our in fluid care pump mission management healthcare fluid with to providing and people conditions. technology our for is by competitive that cost yet overloaded for market to improve a overload alternatives. in heart the advantage suffering We professionals excess alternative patients heart
refine focus to investors our develop metric key a is to potential business judge and Growing the continue our strong shareholders, to demonstrate driving strategic and We performance. by model revenue revenue. will use employees,
to three leading most to contribution to system. third new we marketing commercial One four, identified of continue demonstrative five evidence; execution; advantages; operations, addition opinion salesforce allocate demonstrate physicians. XXXX, build economic health is Aquadex five is revenue's significant In to critical Number sales direct and clinical allocated drive In and offerings; partnerships six revenue provide further is with key we XXXX. quarter and enhanced experienced turnaround. market to salesforce metric expand Management have strategy, in and one, revenue. to business our planned growth two resources to direct increased by a manifest the important actions our to the grow our FlexFlow the strength funding commercial and has is execution product plan for worldwide employees increased
in FlexFlow care unit, Aquadex large the on emergency trained the the team care failure in the unit. hospitals multiple heart department, accounts. Our can and coronary areas large sales focused intensive penetration used system be including The telemetry is hospital sales in floor,
direct customer our support support customers. high expanding to addition servicing to at systems service we technical to salesforce, are quality implementing increase In
based by We the develop Ltd., to with product and We United cardiovascular for also a and products APC support enhancements satisfaction. and strategy. service intend in distribution and have agreement new distributor a improve international initiated our Number entering distribution enhanced Kingdom. product two, to performance products into customer provider offerings
performance. projects several of to and a system access the enhance the have sensor FlexFlow is of to We introduce the peripheral catheter enhance new console. We currently hematocrit that plan Aquadex underway part product functionality
decongest cost to or clinical identify We Aquapheresis develop strategy. patients during ultrafiltration, Number on impacts to rate when evidence system heath clinical care that Aquadex budgetary when amount are expand overload. an FlexFlow published treating heart also to clinical precisely We compares information the be plan support diuretic plan more failed. hospital fluid plan We to and of the strategy. new using measuring fluid overload the hospitals versus of evidence study the the We hospital and patients with support stop evidence plan that to ultrafiltration therapy four, Aquadex patients to use [ph] of three, to continuum to scientific to physicians healthcare for the diuretic therapy. and adopt trial working body of evidence ultrafiltration has system therapy, fluid clinical to into diagnostic causing and therapy the adoption of Aquapheresis publish economic patients mechanism and for whom We for failure their primarily impact to to of cost of significant drive on the how clinically FlexFlow organization tool the effectively with kidneys. reimbursement. initiate harm to an determine of excess provide Number re-hospitalization therapy removed, without ultrafiltration previously a to admitted the action
weight therapy Number to to and plan understanding to for overload. initiate regarding support fluid key of efficacy, opinion advance to attain marketing with customer length leaders reduction, to five, registry build stays, rates. key medical leaders' reduce a We opinion We as identify hospital readmission claims partner feedback strategy. ultrafiltration account demonstrating sets, evidence a also plan clinical use and individual patterns, reduce of treating
We the and a comprised both six help Scientific have implement key clinical develop the recruited study Advisory leading mechanistic of to opinion registry. Board us physicians and
Heart of America. leadership Cardio We role, the Society are a America partnering with involvement Society the of Failure in our increasing with Renal
may fluid several to that care unit In hospital are require the use system provide with but not are addition hospitalization. Aquadex implementing we patients of overload, for are outpatient working that observation physicians FlexFlow
and to Before a use through million manner Fluid is returns is and treatment the lead approximately water the with console per fluid resulting a in over I Ultrafiltration that year similar X overload lengthy of which you trials like and the salt has repeat proprietary consists who process XX% to components; would a prevalent set arm. filtered failed which circuit reduce for is FlexFlow over blood ultrafiltration hospitalizations. remind small price randomized patients, a how to heart turn QX with and is that diuretics the $XXX system with that used patients I the results kidneys overload. from list in Aquadex I a list been details. the heart for to a Claudia price, are diuretic patient over hospitalizations. have patient's that present a and is now blood U.S. who costly can to remove hospitalized to disposable fluid Aquadex dual-lumen and catheter more walk the controlled overload to withdraws temporary simultaneously removes clinical failure therapy. failure unique product that blood There of in has Aquadex you peripheral will a three these Claudia, a acute symptoms pump, our of one-time in $XX,XXX call patients shown primary the to fluid of than patients turn can decompensation condition XXXX financial function. and of in call
I call that, Following closing will and open to comments the we'll some questions. provide
